Artificial Intelligence is one of the most exciting topics of conversation across every industry. And there are few more exciting applications for AI in the life science space than in harnessing it for drug discovery.
We're only just scratching the surface for AI in this market, but to find out more, CM Life Science hosted a webinar featuring three experts in the AI drug discovery space.
We were joined by:
Daniel Meyer - Daniel is CEO of CellChorus, the leader in providing high-throughput dynamic single-cell analysis to the life sciences industry and pioneering the use of AI through their bespoke visual AI platform.
Andrew Radin - Andrew is Co-Founder and Chief Executive Officer of twoXAR (pronounced: “two-czar”), an AI-powered drug discovery and development company focused on first-in-class small molecules.
Brad Pryde - Brad is Co-Founder & COO at OneThree Biotech, a VC backed startup working to change how new medicines are discovered using biology-driven AI.
As CM Life Science's specialist in data science & bioinformatics, I hosted the event and enjoyed it thoroughly. If you have any questions about the webinar or my contacts in this space, please email me at Ben.Paice@lifesci-sm.com.
For more content like this, visit my consultant page.
Alongside the growing trend of value-based searches, I wanted to delve into why candidates prioritise companies that focus on fundamental principles and ethics which resonate with them, as opposed to other more material benefits. Find out why, here.
In this episode, Jack speaks with two Co-Founders at Centivax about life as successful entrepreneurs, the journey to acquisition, challenges and learnings - and using them to become an industry-defining author. Listen now.
In this episode, Jack speaks with Twlya Tiongson Neal, Managing Director at Accenture, about commercial strategy and what this really looks like in the current life science landscape. Click to listen.
Comments.